查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1717871

药物动力学服务市场：按类型、按服务类型、按最终用户 - 2025-2030 年全球预测

Pharmacokinetics Services Market by Type, Service Type, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

药物动力学服务市场预计在 2024 年价值 11.9 亿美元，在 2025 年成长至 13 亿美元，到 2030 年达到 20.1 亿美元，复合年增长率为 9.03%。

主要市场统计数据
基准年2024年 11.9亿美元
预计2025年 13亿美元
预测年份 2030 20.1亿美元
复合年增长率（%） 9.03%

在新技术、复杂的药物开发挑战以及全球对高效治疗解决方案日益增长的需求的推动下，药物动力学服务市场即将经历重大变革。随着准确测量药物的吸收、分布、代谢和排泄变得至关重要，产业相关人员正在重新制定策略，以利用新的机会并解决新的障碍。分析方法的最新进展和新型治疗剂的出现也要求在临床研究和法规遵循方面采取灵活方法。

药物动力学服务目前在药物发现和开发中发挥关键作用，它能够实现准确的数据收集和及时的干预策略，以优化给药方案并提高患者安全性。这个充满活力的领域正在经历将尖端的体外和体内测试与先进的计算模型相结合的综合服务产品的激增。策略创新对于组织应对此复杂局面至关重要，可确保在广泛的治疗领域中取得可靠的成果和竞争差异化。

先进仪器和数位分析技术的引入使得药物动力学具有更重要的战略意义，成为製药和生物技术产业的重要组成部分。因此，相关人员正在大力投资研发倡议，不仅是为了提高药物评估的速度和准确性，也是为了遵守不断发展的全球监管标准。目前的市场动态表明，对最尖端科技的投资和寻求合作研究机会对于该行业的持续成长和成功至关重要。

药物动力学格局的变革

在快速的技术进步和不断变化的客户需求的推动下，药物动力学服务领域正在经历一场变革。近年来，自动化系统和数位资料平台的广泛整合重新定义了传统业务，使得药物评估的方法更加全面。对创新技术的投资最大限度地减少了人为错误，提高了可重复性，并实现了满足现代法律规范严格要求的即时数据分析。

此外，生物製药创新和先进分析的融合导致了向个人化医疗的转变。这种转变不仅仅是技术上的实现；它反映了我们为完善对不同患者群体的药物动力学的理解而做出的更广泛的战略努力。随着产业的适应，融合体外和体内方法的解决方案将变得越来越重要，并且迫切需要整合各种研究模型来优化临床结果。

这段快速变革时期时期也专注于加速药物开发生命週期，同时确保最大的安全性和有效性。新的研究方案加上增强的模拟平台使研究人员能够以前所未有的精确度预测药物行为。这些发展促进了研究机构、技术合作伙伴和监管机构之间的跨职能合作，最终创造出一个数据主导创新可以改变药物发现和治疗开发格局的环境。

利用市场区隔洞察瞄准市场成长

彻底的細項分析将阐明药物动力学服务市场的异质性，并突显可能成长的领域。市场分析主要根据类型、服务类型和最终用户属性进行细分。根据类型，市场传统上分为大分子药物动力学服务和小分子药物动力学服务。生技药品和治疗性蛋白质等大分子由于其复杂的结构，通常需要在药物动力学评估中进行高度专业化的处理，而小分子则带来了经典的分析挑战，这些挑战将继续受益于迭代方法的改进。

此外，按服务类型细分凸显了该行业对体外和体内测试的双重关注。体外部分是基于实验室的实验，为早期药物评估提供受控条件，提供省时且经济的见解。另一方面，体内研究评估药物在活体对像中的行为，提供对理解治疗药物的综合药物动力学特征至关重要的真实世界观点。提供这两种类型的服务的能力使市场开发商能够提供解决整个药物开发生命週期的完整解决方案。

依最终用户进一步细分，凸显了需求方的多样性和复杂性。该市场代表着广泛的客户群体，包括学术和政府研究机构、生物技术公司、委外研发机构和大型製药公司。每个行业都有自己独特的挑战和要求，需要采用量身定制的方法进行研究和服务交付。技术创新者、学术机构和商业公司正在越来越多地调整他们的研究策略，将研究重点放在满足监管和市场期望上。这种多方面的细分框架将使服务供应商能够优化资源配置，调整调查方法，并最终实现客户需求和市场产品之间的更好结合。从这种细分中获得的策略见解将有助于使产品开发和市场进入策略与新兴市场趋势和客户需求保持一致。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 慢性病发病率上升推动了药物动力学服务的使用增加
      • 生技药品和生物相似药的成长将促进药物动力学研究的应用
      • 由于医药品研究开发费用大幅增加，药物动力学评估的重要性日益增加
    • 限制因素
      • 与影响药物动力学服务的药物概况相关的复杂性
    • 机会
      • 整合人工智慧提高药物动力学研究的准确性和效率
      • 个人化医疗的日益普及正在推动药物动力学服务市场的扩张
    • 任务
      • 法规环境复杂，变化频繁，有地区差异
  • 市场区隔分析
    • 类型：个人化医疗需求不断增长推动聚合物药物动力学服务
    • 最终用户：製药和生技公司不断增加的投资推动了药物动力学服务的发展
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

第六章药物动力学服务市场（按类型）

  • 大分子药物动力学服务
  • 小分子药物动力学服务

第七章药物动力学服务市场（依服务类型）

  • 体外
  • 体内

第八章药物动力学服务市场（按最终用户）

  • 学术和政府研究组织
  • 生技公司
  • 合约研究组织
  • 製药公司

9.美洲药物动力学服务市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

10. 亚太地区药物动力学服务市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第 11 章欧洲、中东和非洲药物动力学服务市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Absorption Systems LLC
  • Allucent
  • Aurigene Pharmaceutical Services Ltd.
  • Certara
  • Charles River Laboratories, Inc.
  • Creative Bioarray
  • Eurofins Scientific SE
  • Evotec SE
  • Frontage Laboratories, Inc.
  • ICON PLC
  • Laboratory Corporation of America Holdings
  • LGC Limited by Cinven
  • NUVISAN Pharma Holding GmbH
  • Pacific BioLabs
  • Parexel International（MA）Corporation
  • Pfizer Inc.
  • PPD Inc. by Thermo Fisher Scientific Inc.
  • Premier Consulting
  • Reaction Biology Corporation
  • SGS SA
  • Svar Life Science AB
  • WuXi AppTec Co., Ltd.
  • XenoTech by BioIVT
  • Xyzagen
Product Code: MRR-C002B1C99681

The Pharmacokinetics Services Market was valued at USD 1.19 billion in 2024 and is projected to grow to USD 1.30 billion in 2025, with a CAGR of 9.03%, reaching USD 2.01 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 1.19 billion
Estimated Year [2025] USD 1.30 billion
Forecast Year [2030] USD 2.01 billion
CAGR (%) 9.03%

The pharmacokinetics services market is on the cusp of significant evolution, driven by emerging technologies, complex drug development challenges, and an ever-growing global demand for efficient therapeutic solutions. In a landscape where the accurate measurement of drug absorption, distribution, metabolism, and excretion is paramount, industry stakeholders are refining their strategies to harness new opportunities and address emerging impediments. Recent advancements in analytical methods and the advent of novel therapeutic agents have also necessitated an agile approach in clinical research and regulatory compliance.

Pharmacokinetics services now play a critical role in drug discovery and development by enabling precise data collection and timely intervention strategies that optimize dosing regimens and enhance patient safety. This dynamic field has witnessed a surge in integrated service offerings that combine state-of-the-art in-vitro and in-vivo studies with advanced computational modeling. As organizations navigate this complex terrain, strategic innovation remains a vital ingredient ensuring both robust results and competitive differentiation across a broad spectrum of therapeutic areas.

The introduction of sophisticated instrumentation and digital analytics has further elevated the strategic importance of pharmacokinetics, making it an indispensable facet within the pharmaceutical and biotech industries. Stakeholders are, therefore, investing considerably in research and development initiatives to not only improve the speed and accuracy of drug assessment but also to maintain compliance with evolving global regulatory standards. The current market dynamics signal that investing in cutting-edge technologies and seeking collaborative opportunities will be central to the sustained growth and success of the sector.

Transformative Shifts Reshaping the Pharmacokinetics Landscape

The pharmacokinetics services arena is experiencing transformative shifts powered by rapid technological advancements and evolving customer demands. Over recent years, the widespread integration of automated systems and digital data platforms has redefined traditional practices and enabled a more holistic approach to drug evaluation. Investment in innovative technology has minimized manual errors, enhanced reproducibility, and allowed for real-time data analysis that meets the stringent demands of modern regulatory frameworks.

Furthermore, the convergence of biopharmaceutical innovation and advanced analytics has led to a transformative pivot towards personalized medicine. This shift is not merely about technological adoption but also reflects a broader strategic effort to fine-tune the understanding of drug dynamics in diverse patient populations. As the industry adapts, solutions that merge in-vitro and in-vivo methodologies are assuming greater significance, driving a much-needed integration of various study models to optimize clinical outcomes.

This period of radical transformation is also marked by a keen focus on accelerating the drug development life cycle while ensuring maximum safety and efficacy. New investigative protocols, coupled with enhanced simulation platforms, are allowing researchers to predict drug behavior with unprecedented accuracy. Such developments have encouraged cross-functional collaborations among research institutions, technology partners, and regulatory agencies, ultimately fostering an environment in which innovation driven by data is transforming the landscape of drug discovery and therapeutic development.

Key Segmentation Insights for Targeted Market Growth

A careful segmentation analysis provides a clear view of the heterogeneous nature of the pharmacokinetics services market, illuminating the areas that are primed for growth. The market analysis is primarily categorized based on type, service type, and end-user demographics. When examining the segmentation based on type, the market has been traditionally divided between offerings for large molecules pharmacokinetics services and small molecules pharmacokinetics services. In many cases, large molecules, such as biologics and therapeutic proteins, demand highly specialized handling during pharmacokinetic assessment due to their complex structure, while small molecules bring forward classic analytical challenges that continue to benefit from iterative methodological enhancements.

In addition, segmentation in terms of service type highlights the dual focus of the industry around in-vitro and in-vivo studies. The in-vitro segment represents laboratory-based experiments that provide controlled conditions for early-stage drug evaluation, offering time-efficient and cost-effective insights. Conversely, in-vivo studies bring an essential real-world perspective to the table by evaluating drug behavior in live subjects, which is indispensable for understanding the comprehensive pharmacokinetic profile of therapeutic agents. The ability to provide both types of services allows market players to offer a complete suite of solutions that cater to the complete lifecycle of drug development.

Further segmentation by end-user underscores the diversity and complexity of the demand side. The market landscape encompasses a wide array of clients ranging from academic and government research institutes to biotechnology companies, contract research organizations, and large-scale pharmaceutical companies. Each segment brings its unique challenges and requirements, necessitating a tailored approach to research and service delivery. Technology innovators, academic institutions, and commercial players are increasingly aligning their research strategies to focus on delivers that meet both regulatory and market expectations. This multifaceted segmentation framework enables service providers to optimize resource allocation, tailor their research methodologies, and ultimately achieve better alignment between client needs and market offerings. The strategic insights drawn from this segmentation are instrumental in aligning product development and marketing strategies with emerging trends and client demands.

Based on Type, market is studied across Large Molecules Pharmacokinetics Services and Small Molecules Pharmacokinetics Services.

Based on Service Type, market is studied across In-Vitro and In-Vivo.

Based on End-User, market is studied across Academic & Government Research Institutes, Biotechnology Companies, Contract Research Organizations, and Pharmaceutical Companies.

Emerging Regional Trends Shaping Market Dynamics

The pharmacokinetics services market is hugely influenced by regional trends that dictate regulatory frameworks, innovation capacities, and overall market dynamics. In the Americas, robust infrastructure and a highly developed network of research institutions foster a conducive environment for advanced pharmacokinetic investigations. This region benefits from well-established partnerships between academic and commercial entities, ensuring that the industry remains at the forefront of scientific breakthroughs and regulatory compliance.

Meanwhile, the combined region of Europe, Middle East, and Africa exhibits a diversified landscape where traditional research ecosystems meet emerging technological hubs. The interplay of different regulatory bodies within Europe and the growing innovation pockets in the Middle East and Africa have led to a flexible yet highly competitive environment. The region's diverse market conditions, varying from stringent regulatory oversight in Europe to more agile exploratory approaches in other parts, require service providers to adopt adaptable strategies that balance caution with innovation.

In Asia-Pacific, rapid economic growth combined with strong governmental support for pharmaceutical research has cemented the region's position as a key player in the global pharmacokinetics market. The emphasis on research and development, significant investments in biotechnology, and a surge in academic outputs have stimulated the demand for specialized pharmacokinetic services. The region benefits from a burgeoning talent pool and increased focus on integrating novel methodologies with traditional practices, setting the stage for accelerated market growth over the coming years. Overall, these regional insights point towards the need for global companies to adapt their strategies to cater to varying regional requirements while leveraging emerging trends for sustainable market expansion.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Insights on Leading Companies Driving Market Innovation

An analysis of the key companies active in the pharmacokinetics space reveals a competitive landscape where leaders are continuously pushing the boundaries of scientific innovation and service quality. Industry frontrunners include prominent firms such as Absorption Systems LLC and Allucent, which have built their reputations on delivering robust analytic methodologies that streamline early drug development phases. Other innovators like Aurigene Pharmaceutical Services Ltd. and Certara have become synonymous with excellence in both in-vitro and in-vivo studies, offering comprehensive solutions that address the intricate challenges of modern pharmacokinetics.

Major players such as Charles River Laboratories, Inc. and Creative Bioarray harness advanced technological platforms to deliver precise pharmacokinetic measurements and robust data analytics. The contributions of Eurofins Scientific SE and Evotec SE have redefined industry benchmarks with their combination of expertise and innovative research paradigms. Frontage Laboratories, Inc., ICON PLC, and Laboratory Corporation of America Holdings are further notable examples, consistently pushing the envelope in integrating research methods, streamlining processes, and ensuring regulatory adherence.

The market also sees significant contributions from industry leaders including LGC Limited by Cinven, NUVISAN Pharma Holding GmbH, Pacific BioLabs, Parexel International (MA) Corporation, and Pfizer Inc., whose strategic initiatives are aligned with advancing the drug development life cycle. Additional noteworthy players such as PPD Inc. by Thermo Fisher Scientific Inc., Premier Consulting, Reaction Biology Corporation, SGS SA, Svar Life Science AB, WuXi AppTec Co., Ltd., XenoTech by BioIVT, and Xyzagen collectively drive the competitive intensity and innovation within the pharmacokinetics services market. Their combined efforts in fostering collaboration, investing in new technologies, and streamlining study protocols set the stage for future advancements in drug development and tailored therapeutic strategies.

The report delves into recent significant developments in the Pharmacokinetics Services Market, highlighting leading vendors and their innovative profiles. These include Absorption Systems LLC, Allucent, Aurigene Pharmaceutical Services Ltd., Certara, Charles River Laboratories, Inc., Creative Bioarray, Eurofins Scientific SE, Evotec SE, Frontage Laboratories, Inc., ICON PLC, Laboratory Corporation of America Holdings, LGC Limited by Cinven, NUVISAN Pharma Holding GmbH, Pacific BioLabs, Parexel International (MA) Corporation, Pfizer Inc., PPD Inc. by Thermo Fisher Scientific Inc., Premier Consulting, Reaction Biology Corporation, SGS SA, Svar Life Science AB, WuXi AppTec Co., Ltd., XenoTech by BioIVT, and Xyzagen. Actionable Recommendations for Industry Leaders

Industry leaders must adopt strategic initiatives to maintain a competitive edge in the rapidly evolving pharmacokinetics landscape. First and foremost, investing in novel technological platforms is imperative for increasing both the speed and accuracy of drug evaluation. Leaders should explore opportunities to integrate artificial intelligence and machine learning into data analysis processes, which could streamline study designs and improve predictive outcomes in both in-vitro and in-vivo environments.

Additionally, fostering collaborative partnerships with academic institutions, regulatory agencies, and technology innovators will help bridge the gap between traditional pharmacokinetic methods and emerging trends. Such collaborations should aim at mutual knowledge exchange and co-development of tailored solutions that align with the evolving demands of drug safety and efficacy assessments. Industry players are encouraged to build robust, customizable platforms that can cater to unique client requirements, whether those are driven by the demands of large molecules or small molecules studies.

Adaptability is another crucial factor. Markets are increasingly segmented along various lines, including type, service delivery, and end-user profiles. Leaders must thus ensure that their service portfolios are sufficiently diverse to cater to academic, pharmaceutical, biotechnology, and contract research clients. By aligning service offerings with specific needs and embracing a modular approach to research capabilities, companies can better navigate regulatory changes and shifting market dynamics.

Moreover, advancing training programs and continuous education initiatives will be key to building a workforce prepared to tackle complex research challenges. Emphasizing skill development in emerging analytical techniques and cross-disciplinary methodologies can significantly enhance the quality of study outcomes. In conclusion, a forward-thinking approach that combines investment, collaboration, and meticulous resource management is essential for sustaining long-term growth and operational excellence in the pharmacokinetics services market.

Conclusion: Charting the Future of Pharmacokinetics Services

The evolving dynamics of the pharmacokinetics services market present both significant challenges and exciting opportunities. As the industry continues to integrate innovative technologies and adapt to diverse regional and client segmentation dynamics, the focus on delivering high-quality, compliant, and cost-effective study solutions remains paramount. The combined emphasis on technological advancement, strategic partnerships, and market-specific adaptations is laying a firm foundation for sustained growth and operational excellence.

This comprehensive market analysis underscores the importance of adopting a multifaceted approach that embraces changes in study design, regulatory landscapes, and digital transformation. By driving innovation, aligning service portfolios with specific client needs, and reinforcing global collaborations, industry stakeholders can set new benchmarks in pharmacokinetics services that support the rapid pace of drug discovery and therapeutic innovation. The future is bright for organizations that are prepared to invest in advanced methodologies and adapt dynamically to the constantly shifting market realities.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidence of chronic diseases prompting expanded pharmacokinetic service utilization
      • 5.1.1.2. Growth in biologics and biosimilars fueling enhanced application of pharmacokinetic studies
      • 5.1.1.3. Significant growth in pharmaceutical R&D expenditure elevating the importance of pharmacokinetics assessments
    • 5.1.2. Restraints
      • 5.1.2.1. Complexities associated with drug profiles impacting pharmacokinetics services
    • 5.1.3. Opportunities
      • 5.1.3.1. Integration of artificial intelligence for enhancing accuracy and efficiency of pharmacokinetics studies
      • 5.1.3.2. Increasing popularity of personalized medicine expanding market of pharmacokinetics service
    • 5.1.4. Challenges
      • 5.1.4.1. Complex regulatory landscapes with frequent amendments and regional differences
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Rising demand for personalized medicine boosts the pharmacokinetics services for large molecules
    • 5.2.2. End-User: Increasing investments from pharmaceutical & biotechnology companies driving pharmacokinetics services
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Pharmacokinetics Services Market, by Type

  • 6.1. Introduction
  • 6.2. Large Molecules Pharmacokinetics Services
  • 6.3. Small Molecules Pharmacokinetics Services

7. Pharmacokinetics Services Market, by Service Type

  • 7.1. Introduction
  • 7.2. In-Vitro
  • 7.3. In-Vivo

8. Pharmacokinetics Services Market, by End-User

  • 8.1. Introduction
  • 8.2. Academic & Government Research Institutes
  • 8.3. Biotechnology Companies
  • 8.4. Contract Research Organizations
  • 8.5. Pharmaceutical Companies

9. Americas Pharmacokinetics Services Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Pharmacokinetics Services Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Pharmacokinetics Services Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2024
  • 12.2. FPNV Positioning Matrix, 2024
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. TC BioPharm and CareDx collaborate for enhanced monitoring in cell therapy clinical trial
    • 12.3.2. Sai Life Sciences enhances DMPK capabilities for large-scale collaborations
    • 12.3.3. Frontage Laboratories strengthens European market presence with Accelera acquisition
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Absorption Systems LLC
  • 2. Allucent
  • 3. Aurigene Pharmaceutical Services Ltd.
  • 4. Certara
  • 5. Charles River Laboratories, Inc.
  • 6. Creative Bioarray
  • 7. Eurofins Scientific SE
  • 8. Evotec SE
  • 9. Frontage Laboratories, Inc.
  • 10. ICON PLC
  • 11. Laboratory Corporation of America Holdings
  • 12. LGC Limited by Cinven
  • 13. NUVISAN Pharma Holding GmbH
  • 14. Pacific BioLabs
  • 15. Parexel International (MA) Corporation
  • 16. Pfizer Inc.
  • 17. PPD Inc. by Thermo Fisher Scientific Inc.
  • 18. Premier Consulting
  • 19. Reaction Biology Corporation
  • 20. SGS SA
  • 21. Svar Life Science AB
  • 22. WuXi AppTec Co., Ltd.
  • 23. XenoTech by BioIVT
  • 24. Xyzagen

LIST OF FIGURES

  • FIGURE 1. PHARMACOKINETICS SERVICES MARKET MULTI-CURRENCY
  • FIGURE 2. PHARMACOKINETICS SERVICES MARKET MULTI-LANGUAGE
  • FIGURE 3. PHARMACOKINETICS SERVICES MARKET RESEARCH PROCESS
  • FIGURE 4. PHARMACOKINETICS SERVICES MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 15. AMERICAS PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES PHARMACOKINETICS SERVICES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 17. UNITED STATES PHARMACOKINETICS SERVICES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. PHARMACOKINETICS SERVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 23. PHARMACOKINETICS SERVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PHARMACOKINETICS SERVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PHARMACOKINETICS SERVICES MARKET DYNAMICS
  • TABLE 7. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY LARGE MOLECULES PHARMACOKINETICS SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY SMALL MOLECULES PHARMACOKINETICS SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY IN-VITRO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY IN-VIVO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES PHARMACOKINETICS SERVICES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. PHARMACOKINETICS SERVICES MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 146. PHARMACOKINETICS SERVICES MARKET, FPNV POSITIONING MATRIX, 2024